Ironwood Pharmaceuticals, Inc.
General ticker "IRWD" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $271.1M (TTM average)
Ironwood Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 32.2%.
Estimated limits based on current volatility of 6.0%: low 4.29$, high 4.70$
Factors to consider:
- Total employees count: 267 (+21.9%) as of 2023
- Top business risk factors: Dependency on LINZESS, Insufficient cash flow, Liquidity and credit risks, Acquisition/divestiture risks, Management turnover
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.58$, 8.38$]
- 2025-12-31 to 2026-12-31 estimated range: [4.88$, 8.84$]
Financial Metrics affecting the IRWD estimates:
- Positive: with PPE of 295.8 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 26.50 > 18.33
- Positive: Operating cash flow per share per price, % of 15.08 > 12.91
- Negative: Shareholder equity ratio, % of -85.87 <= 19.35
- Negative: negative Industry operating cash flow (median)
- Negative: Return on assets ratio (scaled to [-100,100]) of 0.25 <= 1.77
- Negative: 0 < Inventory ratio change, % of 0.01
- Negative: Interest expense per share per price, % of 4.81 > 3.31
Short-term IRWD quotes
Long-term IRWD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $410.60MM | $442.74MM | $351.41MM |
| Operating Expenses | $160.26MM | $1,388.16MM | $258.29MM |
| Operating Income | $250.34MM | $-945.43MM | $93.12MM |
| Non-Operating Income | $2.08MM | $-2.64MM | $-27.93MM |
| Interest Expense | $7.60MM | $21.63MM | $33.03MM |
| R&D Expense | $44.27MM | $116.08MM | $111.42MM |
| Income(Loss) | $252.42MM | $-948.07MM | $65.20MM |
| Taxes | $77.36MM | $83.49MM | $64.32MM |
| Profit(Loss)* | $175.06MM | $-1,002.24MM | $0.88MM |
| Stockholders Equity | $652.38MM | $-346.30MM | $-301.33MM |
| Inventory | $1.25MM | $0.00MM | $0.00MM |
| Assets | $1,100.52MM | $471.07MM | $350.91MM |
| Operating Cash Flow | $273.76MM | $183.43MM | $103.55MM |
| Capital expenditure | $0.14MM | $0.27MM | $0.14MM |
| Investing Cash Flow | $-0.14MM | $-1,026.32MM | $-0.14MM |
| Financing Cash Flow | $-237.55MM | $277.16MM | $-106.97MM |
| Earnings Per Share** | $1.13 | $-6.45 | $0.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.